Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02855086 · ClinicalTrials.gov registry record · Phase 1
Cetuximab-IRDye 800CW in Detecting Tumors in Patients With Malignant Glioma Undergoing Surgery
A Phase 1 study, sponsored by Eben Rosenthal.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT02855086: Clinical Trial Phase 1 study, sponsored by Eben Rosenthal.
NCT02855086 is a Phase 1 study that was terminated before completion, run by Eben Rosenthal. The registered enrollment target is 3 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02855086, a Phase 1 study, was terminated before completion, sponsored by Eben Rosenthal.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This study is a phase 1-2 trial that evaluates the best dose of cetuximab-IRDye 800CW and how well it works in detecting tumors in patients with malignant glioma who are undergoing surgery. Cetuximab-IRDye 800CW is an optical imaging agent that may help detect tumor cells when a special camera is used.
Primary Outcome
Tumor to background ratios (TBR) will be generated from still images by comparing the relative fluorescence of normal and tumor tissue. The average fluorescence will be compared to the average fluorescence of the surrounding tissue using the paired student's T test for each specimen.
Interventions
- BIOLOGICAL Cetuximab
- PROCEDURE Tumor resection
- DRUG Cetuximab-IRDye 800CW
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2016-10 |
| Est. Completion | 2016-11-22 |
| Phase | Phase 1 |
Why NCT02855086 stopped before completion
NCT02855086 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 3 interventions - of which Cetuximab is the first listed.
NCT02855086 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02855086 about?
NCT02855086 is a clinical study titled "Cetuximab-IRDye 800CW in Detecting Tumors in Patients With Malignant Glioma Undergoing Surgery". This study is a phase 1-2 trial that evaluates the best dose of cetuximab-IRDye 800CW and how well it works in detecting tumors in patients with malignant glioma who are undergoing surgery. Cetuximab-IRDye 800CW is an optical imaging agent that may help detect tumor cells when a special camera is us...
What is the current status of trial NCT02855086?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2016-10. Estimated completion is 2016-11-22.
What interventions are being tested in trial NCT02855086?
The interventions under investigation include: Cetuximab (BIOLOGICAL), Tumor resection (PROCEDURE), Cetuximab-IRDye 800CW (DRUG).
Who is sponsoring clinical trial NCT02855086?
This trial is sponsored by Eben Rosenthal, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02855086's enrollment target sits among peer trials
3 1999th of 2000 higher than 1 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia